



Recent Advances in Treatment and Diagnosis of Leishmaniasis, Trypanosomiasis and Other Neglected Tropical Diseases

Guest Editor:

Dr. Despina Smirlis

Hellenic Pasteur Institute, Athens,
Greece

Deadline for manuscript
submissions:

closed (31 July 2022)

Message from the Guest Editor

The aim of this Special Issue is the publication of original research articles, reviews, and case reports in order to shed light on NTD diagnosis and drug discovery efforts aiming to circumvent limitations of current chemotherapy.

With respect to drug discovery efforts, the Special Issue will focus on complementary approaches such as molecular target identification and validation, efficacy of new compounds and potential leads, mechanisms of action, docking studies, and others.

The second objective focuses on innovative approaches for diagnosis, epidemiological data showing the recent trends of disease burden, and recent advances that contribute to disease surveillance and to examination of the pathogen genetic background associated with virulence, clinical outcome, and drug resistance.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI